​Moderna Shares Tumble 12% After Full-Year Sales Guidance Slashed – Tyler Durden

Moderna Shares Tumble 12% After Full-Year Sales Guidance Slashed Shares of Moderna tumbled in premarket trading in New York after the biotech slashed its full-year sales guidance. The company cited lower sales in Europe, potential revenue deferrals for certain international sales into 2025, and an “increasingly competitive environment” for respiratory vaccines in the US.   Moderna posted second-quarter earnings that were narrower-than-expected losses and revenue that exceeded the average analyst estimate tracked by Bloomberg. It also posted a loss of $1.28 billion, or $3.33 per share, for the quarter, compared to a net loss of $1.38 billion, or $3.62 per share for the same period one year…  — Continue at ZeroHedge News : Read More